Published in Transplant Proc on August 01, 1995
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med (2013) 7.51
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant (2010) 3.35
Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost (2007) 1.85
Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation (2000) 1.71
Geographical prevalence, risk factors and impact of hepatitis B and C after renal transplantation. Clin Nephrol (2009) 1.51
Cyclosporin-induced muscular toxicity. Lancet (1990) 1.41
CMV infection in the donor and increased kidney graft loss: impact of full HLA-I mismatch and posttransplantation CD8(+) cell reduction. Am J Transplant (2013) 1.40
Comparative evaluation of five different methods for the measurement of plasma factor II levels in carriers of the 20210A prothrombin variant. Blood Coagul Fibrinolysis (2002) 1.40
Relationship between calcineurin inhibition and plasma endothelin concentrations in cyclosporine-A-treated kidney transplant patients. Eur J Clin Pharmacol (2004) 1.39
Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation (2000) 1.33
Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am J Hum Genet (1994) 1.30
Percutaneous transluminal coronary angioplasty immediately after intracoronary streptolysis of transmural myocardial infarction. Circulation (1982) 1.27
Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int (2000) 1.25
The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther (2009) 1.22
Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant (2007) 1.22
Detection of left atrial thrombi by echocardiography. Br Heart J (1981) 1.21
Percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris: analysis of early and late results. Am Heart J (1983) 1.13
Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol (1993) 1.10
Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant (2007) 1.08
Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation (2001) 1.08
Complete thrombolysis of mesenteric vein occlusion with recombinant tissue-type plasminogen activator. Lancet (1988) 1.07
Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer (2005) 1.06
Abnormalities in CD4+ T lymphocyte subsets in patients with common variable immunodeficiency. Clin Immunol Immunopathol (1991) 1.06
Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. Adv Exp Med Biol (1997) 1.03
Anti-CD25 antibodies affect cytokine synthesis pattern of human dendritic cells and decrease their ability to prime allogeneic CD4+ T cells. J Leukoc Biol (2008) 1.03
Interaction of cyclosporin and ticlopidine. Nephrol Dial Transplant (1991) 1.02
Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood (1996) 1.01
High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. Am J Transplant (2010) 1.01
The kinetics of antibodies against hepatitis C virus may predict viral clearance in exposed hemophiliacs. J Infect Dis (1998) 1.00
Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood (2001) 1.00
Improved PCR method for amplification of GC-rich DNA sequences. Mol Biotechnol (2005) 0.99
Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. Lupus (2009) 0.98
Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant (2009) 0.97
Predominant Th1 and cytotoxic phenotype in biopsies from renal transplant recipients with transplant glomerulopathy. Am J Transplant (2009) 0.96
Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol (1999) 0.95
[Arterial hypertension due to mercury poisoning: diagnostic value of captopril]. Arch Pediatr (1995) 0.95
Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost (2011) 0.94
[Gastropericardial fistula. Review of the literature apropos of an original case]. J Chir (Paris) (1990) 0.93
Kidney damage due to tuberous sclerosis complex: management recommendations. Diagn Interv Imaging (2013) 0.93
Characterization and functional analysis of TFPI-2 gene promoter in a human choriocarcinoma cell line. Thromb Res (2003) 0.93
Genetic study of a new X-linked recessive immunodeficiency syndrome. J Clin Invest (1992) 0.92
Deficiency of CD4+CD45R+ T lymphocytes in common variable immunodeficiency. N Engl J Med (1990) 0.92
Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant (2012) 0.92
IL-4, but not tumor necrosis factor-alpha, increases endothelial cell adhesiveness for lymphocytes by activating a cAMP-dependent pathway. J Immunol (1993) 0.90
Human NK cell-mediated direct and IgG-dependent cytotoxicity against xenogeneic porcine endothelial cells. Transpl Immunol (1996) 0.89
Transplant renal artery stenosis: potential role of ischemia/reperfusion injury and long-term outcome following angioplasty. J Urol (1999) 0.88
Hodgkin's disease after transplantation. Transplantation (1996) 0.88
Trophoblast cell line resistance to NK lysis mainly involves an HLA class I-independent mechanism. J Immunol (1999) 0.88
[Diffuse hypertrichosis caused by minoxidil in a 2-and-a-half-year-old child]. Ann Dermatol Venereol (1985) 0.87
Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol (2000) 0.87
A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation (1996) 0.87
Chronic renal failure and portal hypertension--is portosystemic shunt indicated? Pediatr Nephrol (2000) 0.86
Anti-CD25 antibodies decrease the ability of human dendritic cells to prime allogeneic CD4 T cells. Transplant Proc (2009) 0.86
One-year posttransplant renal function is a strong predictor of long-term kidney function: results from the Neoral-MOST Observational Study. Transplant Proc (2003) 0.86
Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch. N Engl J Med (2001) 0.85
In vitro modulation of mouse natural killer (NK) cell activity by the serum thymic factor (FTS). Cell Immunol (1983) 0.85
Modulation of mouse natural killer cell activity by the serum thymic factor. Scand J Immunol (1982) 0.85
Determination of platelet antigens and glycoproteins in the human fetus. Blood (1986) 0.84
Evaluation in patients with Alport syndrome of knowledge of the disease and attitudes toward prenatal diagnosis. Clin Nephrol (1994) 0.84
Compared TCR and CD3 epsilon expression on alpha beta and gamma delta T cells. Evidence for the association of two TCR heterodimers with three CD3 epsilon chains in the TCR/CD3 complex. J Immunol (1995) 0.84
Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol (1997) 0.84
[A syndrome of hyper-IgE and recurrent infections. Developmental variants? A familial study]. Ann Dermatol Venereol (1984) 0.84
End stage coronary disease treated with the transmyocardial CO2 laser revascularization: a chance for the 'inoperable' patient. Eur J Cardiothorac Surg (1997) 0.84
Tumor expression of alternatively spliced tissue factor is a prognostic marker in non-small cell lung cancer. J Thromb Haemost (2009) 0.83
Association between the SDF1-3'A allele and high levels of CD34(+) progenitor cells mobilized into peripheral blood in humans. Br J Haematol (2001) 0.83
Comparative study of the fibrinolytic system in human fetuses and in pregnant women. Thromb Res (1991) 0.83
Cluster of cases of haemolytic uraemic syndrome due to unpasteurised cheese. Pediatr Nephrol (1996) 0.83
Effects of severe protein restriction with ketoanalogues in advanced renal failure. J Am Coll Nutr (1999) 0.83
Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin Thromb Hemost (1985) 0.83
Two-dimensional echocardiographic diagnosis of papillary muscle rupture. Chest (1981) 0.83
[Rheumatoid factors. Isotypes and severity of rheumatoid polyarthritis]. Rev Rhum Mal Osteoartic (1987) 0.83
Polyomavirus-induced acute tubulo-interstitial nephritis in renal allograft recipients. Transplant Proc (2000) 0.83
Acroangiodermatitis in a carrier of the thrombophilic 20210A mutation in the prothrombin gene. Br J Dermatol (1999) 0.83
JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost (2007) 0.82
Interleukin 4 and tumour necrosis factor alpha induce different adhesion pathways in endothelial cells for the binding of peripheral blood lymphocytes. Scand J Immunol (1992) 0.82
Increased lymphocyte adhesion to allogeneic endothelial cells by interleukin-4 (IL-4). Transplant Proc (1991) 0.82
Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay. J Thromb Haemost (2012) 0.82
ELISA for the detection of anticardiolipin antibodies. High specificity based on the use of adult bovine serum as buffer and systematic subtraction of non-specific binding. J Immunol Methods (1991) 0.81
Removal of terminal alpha-galactosyl residues from xenogeneic porcine endothelial cells. Decrease in complement-mediated cytotoxicity but persistence of IgG1-mediated antibody-dependent cell-mediated cytotoxicity. Transplantation (1996) 0.81
Tissue factor activity of syncytiotrophoblast plasma membranes and tumoral trophoblast cells in culture. Thromb Haemost (1995) 0.81
Serum IgG subclass levels in patients with primary immunodeficiency syndromes or abnormal susceptibility to infections. Clin Immunol Immunopathol (1989) 0.81
[Acute leukemia in 3 children with chronic juvenile arthritis treated with chlorambucil]. Arch Fr Pediatr (1979) 0.81
Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transplant (2011) 0.81